Wednesday, July 8, 2026

Patent intelligence · US

US 11155547

Compounds for and methods of treating diseases

granted A61PA61P25/00A61P25/16A61P25/28
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 4
Patent details — US 11155547
Jurisdiction
US
Status
granted
Grant date
Oct 26, 2021
Expiration
Oct 21, 2041
Claims
18
CPC classes
A61P, A61P25/00, A61P25/16, A61P25/28
View on Google Patents ↗

Quick answer

US 11155547 (Compounds for and methods of treating diseases) is held by Alterity Therapeutics Limited. Status: granted. Granted Oct 26, 2021. Expires Oct 21, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
18
CPC classes
A61P, A61P25/00, A61P25/16, A61P25/28

More from Alterity Therapeutics Limited

Related pharmaceutical patents in our USPTO index.

  1. US 11603364

    Acyl hydrazone derivative compounds for treating disease

    Alterity Therapeutics Limited · Expires Mar 9, 2043

    granted
  2. US 11357770

    Method of treating immunoglobulin light chain amyloidosis

    Alterity Therapeutics Limited · Expires Jun 9, 2042

    granted
  3. US 10941143

    Imidazo [1,5-a]pyridine compounds and their use

    Alterity Therapeutics Limited · Expires Mar 4, 2041

    granted

Frequently asked questions

What is US patent 11155547?

US 11155547 (Compounds for and methods of treating diseases) is held by Alterity Therapeutics Limited. Status: granted. Granted Oct 26, 2021. Expires Oct 21, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11155547?

Alterity Therapeutics Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.

When does US 11155547 expire?

Our index shows an expiration date of Oct 21, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.